Skip to Content

Posts tagged with "Business and Markets"

  • Alzheimer's Disease

    Muscarinic Agonists Come Back Around

    Allergan, now that they’re not going to be Pfizer, has wasted no time signing a big deal with Heptares for Alzheimer’s. Heptares, as the receptor-centric people in the readership will know well, has been working on GPCR structure for some years now, and applying this knowledge to their own drug discovery efforts. They have what… Read More
  • Business and Markets

    The Treasury Wins Over Pfizer. Of Course.

    So the Pfizer-Allergan deal has collapsed. The two companys are walking away from it, since under the new rules announced by the Treasury Department, there would be no tax advantages. And this one was all about the taxes – there was no particular drug development or business rationale other than saving a big bucket on… Read More
  • Business and Markets

    Don’t Try to Leave

    The proposed Pfizer-Allergan deal has entered a new stage, and how. You’ll recall that Pfizer has been shopping for years for a way to change its US tax situation, and a merger with Dublin-domiciled Allergan looked like the one that would finally work out. Until last night, that is. That’s when the US Treasury unveiled… Read More
  • Business and Markets

    An Old Problem at Verily

    Stat has a very interesting report on what’s going on at one of Google’s biomedical companies, Verily Life Sciences. They get right down to it in the opening: Google’s brash attempt to revolutionize medicine as it did the Internet is facing turbulence, and many leaders who launched its life sciences startup have quit, STAT has found. Read More
  • Business and Markets

    You Ask For It; You Get It

    So Valeant is getting rid of their CEO, the not-so-beloved Michael Pearson, and has started to come clean about accounting problems at the company. This statement is of particular interest: The improper conduct of the company’s former Chief Financial Officer and the former Corporate Controller, which resulted in the provision of incorrect inf… Read More
  • Business and Markets

    What We Can Learn From Valeant’s Wreckage

    The Valeant wreckage continues to smolder, and it will remain a tourist attraction for students of forensic accounting techniques for some time to come. For an informative look at the accounts of the people who have been holding its stock, check in with Matt Levine at Bloomberg. He’s gone through the public filings of Bill… Read More
  • Business and Markets

    Chemical Evolution Makes a Deal

    Sanofi has signed a deal with a Stanford-born startup called DiCE Molecules, looking for small-molecule inhibitors of protein-protein interactions. So who are these folks and what route do they have into this perpetually promising-and-challenging area? DiCE grew out of work at Pehr Harbury’s group at Stanford. The company’s web site mak… Read More
  • Business and Markets

    Valeant Implodes

    You might have noticed what happened to Valeant Pharmaceuticals yesterday. I was traveling and unable to blog about it during the afternoon, but it was quite a spectacle. This has, of course, been a long-running saga, with plenty of damaging revelations by people shorting the stock (and plenty of rebuttals from the company and outright… Read More
  • Business and Markets

    Getting It Done Here – Or Not

    Outsourcing of chemistry is not quite the hot-button issue it was a few years ago, but it’s still very much with us. All sorts of US firms get work done in China or India, small scale to large, and there’s little doubt that twenty years ago the greater part of this would likely have been… Read More
  • Business and Markets

    Codexis Says They’ve Been Ripped Off

    I mentioned enzyme engineering briefly the other day, and that, of course, is where companies like Codexis make their living. They made a big splash with Merck a few years ago, and are continuing to work with a variety of partners to industrialize tricky enzymatic transformations. Well, now they’re accusing a former employee of Pfizer… Read More